BCRXBiocryst Pharmaceuticals Inc.

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect...

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.

Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BCRX stock climbed past its key resistance at $10.32 to hit a record high earlier in the session, before paring most of the gains.

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...